EMA Approval And AI Integration Will Drive Biosimulation Despite Risks

Published
08 Jun 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$14.11
22.3% undervalued intrinsic discount
08 Aug
US$10.97
Loading
1Y
-9.8%
7D
-2.6%

Author's Valuation

US$14.1

22.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25
Fair value Decreased 2.31%

The slight downward revision in Certara’s price target reflects a modest reduction in its future P/E ratio, while revenue growth expectations remain essentially unchanged, resulting in a new consensus price target of $14.11. What's in the News Certara reiterated full-year 2025 revenue guidance of $415 million to $425 million.